Table 2.

Multivariate adjusted Hazard Ratios and 95 % Confidence Interval for HF therapy initiation

		HR (95% CI)*	P-value
RAS inhibitor	Kidney function at baseline
	eGFR ≥60	Reference
	eGFR 30-59	0.97 (0.93-1.02)	0.198
	eGFR <30	0.44 (0.40-0.49)	<0.0001
	Age
	<65	Reference
	65≤age<80	1.00 (0.96-1.05)	0.847
	≥80	0.72 (0.69-0.75)	<0.0001
	Frailty risk group
	Low	Reference
	Intermediate	0.72 (0.69-0.75)	<0.0001
	High	0.49 (0.45-0.53)	<0.0001
MRA	Kidney function at baseline
	eGFR ≥60	Reference
	eGFR 30-59	0.80 (0.77-0.83)	<0.0001
	eGFR <30	0.24 (0.21-0.27)	<0.0001
	Age
	<65	Reference
	65≤age<80	0.97 (0.93-1.01)	0.111
	≥80	0.68 (0.64-0.71)	<0.0001
	Frailty risk group
	Low	Reference
	Intermediate	0.84 (0.81-0.88)	<0.0001
	High	0.60 (0.56-0.66)	<0.0001
BB	Kidney function at baseline
	eGFR ≥60	Reference
	eGFR 30-59	1.09 (1.05-1.14)	<0.0001
	eGFR <30	1.06 (0.97-1.16)	0.186
	Age
	<65	Reference
	65≤age<80	0.91 (0.87-0.95)	<0.0001
	≥80	0.61 (0.58-0.65)	<0.0001
	Frailty risk group
	Low	Reference
	Intermediate	0.73 (0.70-0.76)	<0.0001
	High	0.51 (0.47-0.55)	<0.0001

Notes: *In addition, adjusted for concomitant pharmacotherapy, comorbidity, outpatient status and sex (estimates not shown).

Abbreviations: eGFR, estimated glomerular filtration rate; HR, hazard ratio; CI, confidence interval; RAS, renin-angiotensin receptor antagonists; MRA, mineralocorticoid receptor antagonist; BB, betablocker.